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Abstract Human mast cells (HMC-1) take up anandamide
(arachidonoyl-ethanolamide, AEA) with a saturable process
(Km = 200 þ 20 nM, Vmax = 25 þ 3 pmol min31 mg protein31),
enhanced two-fold over control by nitric oxide-donors. Inter-
nalized AEA was hydrolyzed by a fatty acid amide hydrolase
(FAAH), whose activity became measurable only in the presence
of 5-lipoxygenase, but not cyclooxygenase, inhibitors. FAAH
(Km = 5.0 þ 0.5 WM, Vmax = 160 þ 15 pmol min31 mg protein31)
was competitively inhibited by palmitoylethanolamide. HMC-1
cells did not display a functional cannabinoid receptor on their
surface and neither AEA nor palmitoylethanolamide affected
tryptase release from these cells.
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1. Introduction
Mast cells are multifunctional bone marrow-derived cells
found in mucosal and connective tissues and in the nervous
system, where they play essential roles in ¢brosis, angiogene-
sis, in£ammation and neuroimmune interactions [1,2]. As yet,
little is known about endogenous modulators and mechanisms
of mast cell activation. Anandamide (arachidonoylethanola-
mide, AEA) and palmitoylethanolamide (PEA) belong to an
emerging class of endogenous lipids including amides and es-
ters of long chain polyunsaturated fatty acids, termed collec-
tively ‘endocannabinoids’ [3]. These compounds mimic the
pharmacological e¡ects of v9-tetrahydrocannabinol, the active
principle of hashish and marijuana, by binding to cannabinoid
receptors (CBR) [4]. Two types of CBR have been character-
ized, which di¡er for their ligand selectivity and a⁄nity, and
for their distribution: type 1 receptors (CB1R) are present in
the central nervous system and in peripheral tissues, whereas
type 2 receptors (CB2R) are present only in peripheral cells
[4]. Recently, rat mast cells were reported to express a func-
tional CB2R, which could bind AEA and PEA [5]. Only bind-
ing of PEA to CB2R was found to down-regulate mast cell
activation and, thus, in£ammation [5]. However, the ability of
PEA to activate CB2R is under debate (reviewed by Lambert
and Di Marzo [6]) and AEA has been shown to reduce in-
£ammation in whole rats via interaction with CB1R [7]. On
the other hand, the peripheral endocannabinoid system is ac-
tivated during human shock conditions, such as hemorrhagic
and septic shock [8] and mediates also the response to endo-
toxins [9]. Therefore, attention is being focused on the ability
of peripheral cells to degrade endocannabinoids, by a two-step
process including (i) cellular uptake by a speci¢c AEA trans-
porter and (ii) intracellular degradation by the enzyme fatty
acid amide hydrolase (FAAH). This degradation machinery
has been shown in peripheral rat cells [10], human lymphoma
cells [11] and human platelets [12]. The identity of physiolog-
ical regulators of the endocannabinoid degradation remains
elusive [11,12]. Also the contribution of mast cells in regulat-
ing the peripheral actions of endocannabinoids is still un-
known. This prompted us to investigate the ability of the
HMC-1 human mast cell line to take up and hydrolyze
AEA and how degradation of this lipid might be controlled.
Also the presence of a functional cannabinoid receptor in
HMC-1 cells was assessed. Moreover, the possible role of
AEA and PEA in tryptase release from HMC-1 cells was
investigated. Tryptases are trypsin-like proteinases stored in
the cytoplasmic granules of mast cells from several organisms
[13,14]. Their release upon degranulation is a marker of mast
cell activation [1,2].z
2. Materials and methods
2.1. Materials
Chemicals were of the purest analytical grade. Anandamide (arach-
idonoylethanolamide, AEA), arachidonic acid, A23187, 5,8,11,14-ei-
cosatetraynoic acid (ETYA), indomethacin, ibuprofen, hydroxocobal-
amin, sodium nitroprusside (SNP) and N-p-tosyl-Gly-Pro-Lys-p-
nitroanilide (TGPL) were purchased from Sigma (St. Louis, MO,
USA). Arachidonoyl-tri£uoromethyl-ketone (ATFMK), S-nitroso-N-
acetylpenicillamine (SNAP) and N-(4-hydroxyphenyl)-arachidonoyl-
amide (AM404) were from Research Biochemicals International
(Natick, MA, USA). Leukotriene B4 and prostaglandin E2 were
from Cayman Chemical Company (Ann Arbor, MO, USA). [3H]-
CP55.940 (5-(1,1P-dimethyheptyl)-2-[1R,5R-hydroxy-2R-(3-hydroxy-
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propyl)cyclohexyl]phenol, 126 Ci/mmol) and [3H]AEA (223 Ci/mmol)
were purchased from NEN Dupont de Nemours (Ko«ln, Germany). 5-
Lipoxygenase speci¢c inhibitor 3-[1-(p-chlorobenzyl)-5-(isopropyl)-3-
tert-butylthioindol-2-yl]-2,2-dimethyl propanoic acid (MK886) was a
kind gift from Dr. A.W. Ford-Hutchinson (Merck Frosst Centre for
Therapeutic Research, Pointe Claire-Dorval, Canada). Palmitoyletha-
nolamide (PEA) was synthesized and characterized (puritys 96% by
gas^liquid chromatography) as reported [15]. Rabbit anti-human
CB1R polyclonal antibodies were from Calbiochem (La Jolla, CA,
USA).
2.2. Cell culture
The human mast cell line HMC-1 was kindly provided by Dr. J.H.
Butter¢eld (Division of Allergic Diseases, Mayo Clinic, Rochester,
MN, USA). HMC-1 cells were cultured as described [16]. Cells at
the fourth^¢fth passage were harvested, washed in phosphate-bu¡ered
saline and used for biochemical assays, as detailed below. Cell vi-
ability was assessed in a Neubauer chamber by trypan blue dye ex-
clusion.
2.3. Determination of anandamide uptake
The uptake of [3H]AEA by intact HMC-1 cells (2U106) was studied
essentially as described [11]. To discriminate non-carrier-mediated
from carrier-mediated transport of AEA through cell membranes,
control experiments were carried out at 4‡C [11]. The Q10 value was
calculated as the ratio of AEA uptake at 30 and 20‡C [17]. Apparent
Km and Vmax of the uptake were determined by Lineweaver^Burk
analysis [11]. The e¡ect of di¡erent compounds on AEA uptake (15
min) was determined by adding each substance directly to the incu-
bation medium, at the indicated concentrations. The cell viability after
each treatment was higher than 90% in all cases.
2.4. Assay of fatty acid amide hydrolase (FAAH)
Fatty acid amide hydrolase (EC 3.5.1.4; FAAH) activity was as-
sayed at pH 9.0 in HMC-1 cell homogenates, prepared as reported
[18], by reversed phase high performance liquid chromatography [18].
Kinetic studies were performed as described [11].
2.5. Analysis of cannabinoid receptors
Membrane fractions were prepared from HMC-1 cells (2U108) as
reported [15]. These membranes and those prepared from the brain of
Wistar rats (male, weighing 250^280 g) were used in rapid ¢ltration
assays with the synthetic cannabinoid [3H]CP 55.940 (400 pM) [15].
Unspeci¢c binding was determined in the presence of 10 WM AEA
[15].
SDS^polyacrylamide gel electrophoresis (12%) was performed
under reducing conditions [11] on cell homogenates (25 Wg/lane), pre-
pared as described [18] and was followed by electroblotting onto 0.45
Wm nitrocellulose ¢lters (Bio-Rad, Hercules, CA, USA) [11]. Pre-
stained molecular weight markers (Bio-Rad) were bovine serum albu-
min (84 kDa) and ovalbumin (47 kDa). Human brain specimens were
homogenized as reported [11]. Immunodetection of CB1R was per-
formed with speci¢c anti-human CB1R polyclonal antibodies, diluted
1:400, and goat anti-rabbit immunoglobulins conjugated with alkaline
phosphatase (GAR-AP, Bio-Rad) at 1:2000 dilution [11].
2.6. Tryptase release
Tryptase secretion from HMC-1 cells (6U106) was stimulated for
8 h with 500 ng/ml A23187 at 37‡C [2], in the presence or absence of
AEA or PEA (10 WM). Cell suspensions were centrifuged at 1000Ug
for 10 min and tryptase was assayed in the cell-free supernatants [2].
Residual tryptase in the packed cells was released by sonication in 10
mM MES bu¡er (pH 6.1), containing 1 M NaCl. Tryptase activity
was measured by adding each sample (100 Wl) to 1 ml of 0.1 mM
TGPL substrate in 50 mM Tris^HCl, pH 7.4, and by monitoring
product formation at 405 nm [2]. The release of tryptase was calcu-
lated by the equation: (released tryptase/(released tryptase+cell-asso-
ciated tryptase))U100.
2.7. Statistical analysis
Data reported in this paper are the mean ( þ S.D.) of at least three
independent determinations, each in duplicate. Statistical analysis was
performed by the Student’s t-test, elaborating experimental data by
means of the InStat program (GraphPad Software for Science, CA,
USA).
3. Results
Intact HMC-1 cells were able to accumulate [3H]AEA, in a
temperature- (Q10 = 1.7), time- (t1=2 = 4 min) and concentra-
tion-dependent manner (Fig. 1A and data not shown).
[3H]AEA uptake at 37‡C was saturable (apparent
Km = 200 þ 20 nM, Vmax = 25 þ 3 pmol min31 mg protein31)
and was almost completely inhibited by the speci¢c AEA
transport inhibitor AM404 [19]. The uptake was enhanced
dose-dependently when incubations were carried out in the
presence of NO donors SNP or SNAP (Fig. 1B). These do-
nors were used at millimolar concentrations which release
physiological nanomolar concentrations of NO in solution
[20]. Enhancement of [3H]AEA uptake by SNP was prevented
by hydroxocobalamin (Fig. 1B), a typical NO scavenger [21].
Fig. 1. A: Dependence of [3H]AEA uptake by intact HMC-1 cells
(15 min) on AEA concentration, at 37 (circles) or 4‡C (triangles).
The asterisk indicates the e¡ect of 10 WM AM404 on the uptake of
1 WM AEA at 37‡C. B: E¡ect of nitric oxide-donors SNP (empty
bars) or SNAP (hatched bars) on the uptake of 200 nM [3H]AEA
at 37‡C. The e¡ect of 0.5 mM hydroxocobalamin on the [3H]AEA
uptake in the presence of 10 mM SNP is shown by the dotted bar.
Uptake was expressed as percentage increase over the untreated
control (100% = 10 þ 1 pmol min31 mg protein31). *Denotes
P6 0.01 compared with control; **denotes P6 0.01 compared with
10 mM SNP.
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Moreover, uptake of 200 nM [3H]AEA in the presence of
arachidonic acid, PEA, leukotriene B4 or prostaglandin E2
(each used at 2 WM) was approximately 90% of the control
in all cases, suggesting that AEA accumulation was selective.
HMC-1 cells did not show basal FAAH activity at pH 9.0,
which became measurable upon addition of 20 WM MK886 or
ETYA, both 5-lipoxygenase inhibitors [22], to the FAAH as-
say bu¡er (Fig. 2A). Under the same experimental conditions,
20 WM indomethacin or ibuprofen, both cyclooxygenase in-
hibitors [23], were ine¡ective (Fig. 2A). In the presence of 20
WM ETYA, FAAH hydrolyzed AEA in a Michaelis^Menten
way (Fig. 2B), showing an apparent Km of 5.0 þ 0.5 WM and a
Vmax of 160 þ 15 pmol min31 mg protein31. HMC-1 FAAH
was completely inhibited by 10 WM ATFMK, a speci¢c
FAAH inhibitor [24] and was inactive at pH 5.0. Interestingly,
PEA inhibited FAAH-catalyzed hydrolysis of AEA with an
IC50 of 20 þ 2 WM, acting as a competitive inhibitor with an
inhibition constant of 10 þ 1 WM.
Unlike rat brain membranes, used as a positive control,
HMC-1 cells were unable to bind [3H]CP55.940 (Fig. 3), a
synthetic cannabinoid which binds with high a⁄nity both
CB1R and CB2R [4]. Western blot analysis showed that
HMC-1 cells, unlike human brain used as a positive control,
did not react with speci¢c anti-human CB1R antibodies (Fig.
3, inset).
Tryptase release from HMC-1 cells stimulated with calcium
ionophore A23187 reached approximately 15%, compared to
a spontaneous level 6 2% (Fig. 4). AEA or PEA did not
induce tryptase release from HMC-1 cells, neither a¡ected
the release triggered by A23187, when used at 10 WM (Fig.
4) or up to 50 WM (not shown).
4. Discussion
HMC-1 cells have a speci¢c AEA transporter and a FAAH,
characterized here for the ¢rst time. The a⁄nity of the trans-
porter for AEA in HMC-1 was very close to that of human
lymphoma (130 nM) [11] and identical to that of human plate-
lets [12]. Therefore, the same carrier might be present on the
surface of peripheral human cells. As reported for human
lymphoma [11] and platelets [12], AEA uptake by HMC-1
cells was increased by NO-donors SNP or SNAP (Fig. 1B).
This suggests an inverse relationship between NO and AEA,
which is noteworthy if one recalls that NO is a pro-in£amma-
tory agent [25], whereas AEA exerts an opposite action in rats
[7].
A major ¢nding of this investigation is that HMC-1 cells
have negligible basal levels of FAAH activity, which becomes
remarkable in the presence of speci¢c 5-lipoxygenase inhibi-
tors (Fig. 2A). This is noteworthy, because hydroperoxides
generated from AEA by lipoxygenase have been recently
shown to be potent (Ki as low as 3 WM) inhibitors of
FAAH [11]. Since HMC-1 cells express an active 5-lipoxygen-
ase [26], it can be suggested that AEA used as a substrate to
assay FAAH is converted instead by 5-lipoxygenase into hy-
droperoxides, which inhibit FAAH activity. It must be men-
tioned that MK886 can exert also lipoxygenase-unrelated ef-
Fig. 2. A: E¡ect of 5-lipoxygenase inhibitors MK886 and ETYA,
or cyclooxygenase inhibitors indomethacin and ibuprofen, on
FAAH activity in HMC-1 cells. B: Dependence of HMC-1 FAAH
activity, assayed in the presence of 20 WM ETYA, on substrate con-
centration. *Denotes P6 0.01 compared with control; **denotes
Ps 0.05 compared with control.
Fig. 3. Displacement of the synthetic cannabinoid [3H]CP55.940 by
AEA in rat brain (circles) or HMC-1 (triangles) cell membrane
preparations. Inset: Western blot analysis of human brain (A) or
HMC-1 cells (B) extracts (25 Wg/lane), reacted with speci¢c anti-hu-
man CB1R polyclonal antibodies. Molecular weight markers are
shown on the right-hand side and arrow indicates the expected mo-
lecular mass of CB1R.
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fects on mammalian cells [27]. However, the observation that
ETYA and MK886 yielded the same e¡ects on HMC-1
FAAH seems to rule out lipoxygenase-independent pathways.
In this context it is worth reminding that NO inhibits lipoxy-
genase activity [28]. Therefore, it can be proposed that NO
reduces hydroperoxide formation from AEA, thus preventing
inhibition of FAAH. This would result in a faster dissipation
of the AEA gradient, leading to enhanced uptake of this lipid.
The interplay between NO, 5-lipoxygenase and FAAH might
contribute to activation of AEA transport, together with a
direct e¡ect of NO on the carrier, e.g. through nitrosylation
of cysteine residues [11]. AEA can be metabolized also by
cyclooxygenase activity [29], which is abundant in HMC-1
cells [26]. However, these AEA metabolites do not seem to
inhibit FAAH, because cyclooxygenase inhibitors were unable
to ‘disclose’ its activity (Fig. 2A). In the presence of ETYA,
HMC-1 FAAH showed catalytic properties comparable to
those of human lymphoma [11] and human platelets [12].
Remarkably, PEA acted as a competitive inhibitor of
FAAH, which favors the hypothesis that it is an ‘entourage
compound’ for endocannabinoids, i.e. an enhancer of their
activity through inhibition of their inactivation [6]. Finally,
the lack of FAAH activity at pH 5.0 rules out the possibility
that HMC-1 FAAH might be the new AEA-hydrolyzing en-
zyme recently found in lysosomes and mitochondria [30].
Unlike rat mast cells [5], human mast cells do not express
functional cannabinoid receptors on their surface (Fig. 3). The
availability of anti-human CB1R antibodies allowed to cor-
roborate the binding data for this receptor subtype (Fig. 3,
inset). The lack of cannabinoid receptors in HMC-1 cells
seems interesting, because CB2R in rat mast cells [5] and
peripheral CB1R in whole rats [7] have been proposed to
down-regulate in£ammation. However, endocannabinoids
can act also independently of cannabinoid receptors [3], there-
fore the possibility that AEA or PEA might modulate HMC-1
activation was investigated. Tryptase release was used as a
marker [2]. Unlike rat mast cells [5], human mast cells were
not down-modulated by AEA or PEA, which did not interfere
with spontaneous or A23187-triggered degranulation (Fig. 4).
Taken together, these ¢ndings suggest major di¡erences be-
tween rats and humans in mast cell activation and do not
favor the hypothesis of an autacoid local in£ammation antag-
onism (ALIA) mechanism [5] in humans. On the other hand,
the ability of HMC-1 to take up AEA, and to hydrolyze it
under 5-lipoxygenase control, suggests that mast cells can
contribute to regulate the peripheral endocannabinoid system,
hence the actions of these lipid mediators in in£ammation,
vascular tone and neuroimmune interactions.
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